Anti-NMDAR2A antibody [EPR2465(2)],Abcam,AB124913

Patented technology Our RabMAb ® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb ® patents . What are the advantages of a recombinant monoclonal antibody? This product is a recombinant monoclonal antibody, which offers several advantages including: - High batch-to-batch consistency and reproducibility - Improved sensitivity and specificity - Long-term security of supply - Animal-free batch production For more information, read more on recombinant antibodies .

Host

Rabbit

Reactivity

Mouse, Rat, Human

Application

WB

Platform ID

BAB840419607

Abcam

Headquarters

Discovery Drive Cambridge Biomedical Campus Cambridge CB2 0AX UK

Contact

Tel: +44 (0)1223 696000
Fax: +44 (0)1223 215 215

Product Specifications
Scientific Background

Specifications

NameAnti-NMDAR2A antibody [EPR2465(2)]
Cat. No.AB124913
HostRabbit
IsotypeIgG
ReactivityMouse, Rat, Human
ApplicationWB
ClonalityMonoclonal
Clone NumberEPR2465(2)
Concentration1.873 mg/mL Batch dependent concentration
ImmunogenThe exact immunogen used to generate this antibody is proprietary information.
PurityAffinity purification Protein A
Appearance/FormLiquid
ShippingBlue Ice
FormulationpH: 7.2 - 7.4 Preservative: 0.01% Sodium azide Constituents: PBS, 40% Glycerol (glycerin, glycerine), 0.05% BSA
Storage-20°C
Regulatory StatusResearch Use Only

Scientific Background

Target data Component of N-methyl-D-aspartate (NMDA) receptors (NMDARs) that function as heterotetrameric, ligand-gated cation channels with high calcium permeability and voltage-dependent block by Mg(2+) (PubMed : 20890276, PubMed : 23933818, PubMed : 23933819, PubMed : 23933820, PubMed : 24504326, PubMed : 26875626, PubMed : 26919761, PubMed : 28242877, PubMed : 36117210, PubMed : 38538865, PubMed : 8768735). NMDARs participate in synaptic plasticity for learning and memory formation by contributing to the slow phase of excitatory postsynaptic current, long-term synaptic potentiation, and learning (By similarity). Channel activation requires binding of the neurotransmitter L-glutamate to the GluN2 subunit, glycine or D-serine binding to the GluN1 subunit, plus membrane depolarization to eliminate channel inhibition by Mg(2+) (PubMed : 23933818, PubMed : 23933819, PubMed : 23933820, PubMed : 24504326, PubMed : 26875626, PubMed : 26919761, PubMed : 27288002, PubMed : 28095420, PubMed : 28105280, PubMed : 28126851, PubMed : 28182669, PubMed : 29644724, PubMed : 38307912, PubMed : 8768735). NMDARs mediate simultaneously the potasium efflux and the influx of calcium and sodium (By similarity). Each GluN2 subunit confers differential attributes to channel properties, including activation, deactivation and desensitization kinetics, pH sensitivity, Ca2(+) permeability, and binding to allosteric modulators (PubMed : 26875626, PubMed : 26919761). Participates in the synaptic plasticity regulation through activation by the L-glutamate releaseed by BEST1, into the synaptic cleft, upon F2R/PAR-1 activation in astrocyte (By similarity). See full target information GRIN2A

Category Paths

Request a product

Please provide the required information below so that we can quickly source your products.